These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8602023)

  • 61. Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease.
    Alexander F; Matheson M; Fry NK; Labram B; Gorringe AR
    Clin Vaccine Immunol; 2012 Nov; 19(11):1776-83. PubMed ID: 22956654
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development.
    Carbonetti NH; Wirsing von König CH; Lan R; Jacob-Dubuisson F; Cotter PA; Deora R; Merkel TJ; van Els CA; Locht C; Hozbor D; Rodriguez ME
    Clin Vaccine Immunol; 2016 Nov; 23(11):842-850. PubMed ID: 27655886
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities.
    Halperin SA; Barreto L; Eastwood BJ; Law B; Roberts EA
    Arch Pediatr Adolesc Med; 1994 Nov; 148(11):1220-4. PubMed ID: 7921131
    [No Abstract]   [Full Text] [Related]  

  • 64. Antigenic analysis of the saccharide moiety of the lipooligosaccharide of Bordetella pertussis.
    Brodeur BR; Martin D; Hamel J; Shahin RD; Laferrière C
    Springer Semin Immunopathol; 1993; 15(2-3):205-15. PubMed ID: 8256198
    [No Abstract]   [Full Text] [Related]  

  • 65. An antigen-conserving ELISA for detecting human antibodies to Bordetella pertussis filamentous hemagglutinin.
    Vernon SK; Wiener FP; Urbano C; Levner MH
    J Biol Stand; 1986 Apr; 14(2):157-61. PubMed ID: 2876000
    [No Abstract]   [Full Text] [Related]  

  • 66. Pertussis: the trials and tribulations of old and new pertussis vaccines.
    Cherry JD
    Vaccine; 1992; 10(14):1033-8. PubMed ID: 1471425
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Diversion of complement-mediated killing by Bordetella.
    Thiriard A; Raze D; Locht C
    Microbes Infect; 2018; 20(9-10):512-520. PubMed ID: 29454132
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pertussis antibodies in vaccinated children.
    Preston NW
    Lancet; 1983 Nov; 2(8360):1197. PubMed ID: 6139553
    [No Abstract]   [Full Text] [Related]  

  • 69. Immunogenicity and protective efficacy of pertussis toxin subunit S1 produced by Bacillus subtilis.
    Olander RM; Muotiala A; Himanen JP; Karvonen M; Airaksinen U; Runeberg-Nyman K
    Microb Pathog; 1991 Feb; 10(2):159-64. PubMed ID: 1909767
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Responses to acellular pertussis vaccines and component antigens in a coughing-rat model of pertussis.
    Hall E; Parton R; Wardlaw AC
    Vaccine; 1998 Oct; 16(17):1595-603. PubMed ID: 9713934
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acellular pertussis vaccines--a solution to the pertussis problem?
    Edwards KM
    J Infect Dis; 1993 Jul; 168(1):15-20. PubMed ID: 8515102
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Optimal Timing of Immunization Against Pertussis During Pregnancy.
    Abu Raya B; Srugo I; Bamberger E
    Clin Infect Dis; 2016 Jul; 63(1):143-4. PubMed ID: 27090990
    [No Abstract]   [Full Text] [Related]  

  • 73. Specific IgE-antibodies to Bordetella pertussis antigens during whooping cough.
    Wirsing von Koenig CH; Finger H
    Lancet; 1989 Apr; 1(8640):728. PubMed ID: 2564540
    [No Abstract]   [Full Text] [Related]  

  • 74. Proteomics-identified Bvg-activated autotransporters protect against bordetella pertussis in a mouse model.
    de Gouw D; de Jonge MI; Hermans PW; Wessels HJ; Zomer A; Berends A; Pratt C; Berbers GA; Mooi FR; Diavatopoulos DA
    PLoS One; 2014; 9(8):e105011. PubMed ID: 25133400
    [TBL] [Abstract][Full Text] [Related]  

  • 75. International symposium on pertussis evaluation and research on acellular pertussis vaccines. National Institute of Health in Tokyo and International Association of Biological Standardization. 14-15 September 1990 at Shizuoka, Japan.
    Biologicals; 1991 Apr; 19(2):145-9. PubMed ID: 1888495
    [No Abstract]   [Full Text] [Related]  

  • 76. [Bordetella pertussis agglutinogens in cultivation dynamics].
    Basnak'ian IA; Aleksakhina NN; Shelemekh OV; Miriasova LV; Siundiukova RA
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (3):37-42. PubMed ID: 17672129
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases.
    Damron FH; Barbier M; Dubey P; Edwards KM; Gu XX; Klein NP; Lu K; Mills KHG; Pasetti MF; Read RC; Rohani P; Sebo P; Harvill ET
    J Immunol; 2020 Aug; 205(4):877-882. PubMed ID: 32769142
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [The expression of Bordetella pertussis protective antigens during bacterial multiplication on a medium with a fixed chemical composition].
    Shmeleva EI; Mertsalova NU; Sukhinova EV; Kirillova GA; Remova TN; Bazhanova IG; Ozeretskovskaia MN; Britsina MV; Ermolova EV; Zakharova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (2):47-50. PubMed ID: 9245141
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Interrelation of the toxicity and capacity of pertussis vaccines to alter the body immune response to heterogenetic antigens].
    Levina LA; Elkina SI; Beĭlina VB; Prilepin NA; Kalina NG
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Jan; (1):75-9. PubMed ID: 6282013
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Boosting understanding of pertussis outbreaks.
    Grenfell B
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7279-80. PubMed ID: 21508325
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.